Obinutuzumab Delays Progression in Advanced Follicular Lymphoma

News
Article

Treatment with obinutuzumab along with chemotherapy resulted in longer progression-free survival than rituximab and chemotherapy in patients with previously untreated advanced-stage follicular lymphoma, according to a large randomized trial.

Treatment with obinutuzumab along with chemotherapy resulted in longer progression-free survival than rituximab and chemotherapy in patients with previously untreated advanced-stage follicular lymphoma, according to a large randomized trial.

“The combination of the anti-CD20 monoclonal antibody rituximab with chemotherapy has significantly improved outcomes in patients with newly diagnosed follicular lymphoma,” wrote study authors led by Robert Marcus, MD, of King’s College Hospital in London. Obinutuzumab is also an anti-CD20 monoclonal antibody, and it has been shown to have significant antitumor activity in other malignancies.

The GALLIUM trial included 1,202 patients with follicular lymphoma, randomized to undergo induction treatment with either obinutuzumab-based chemotherapy (601 patients) or rituximab-based chemotherapy (601 patients). Patients who had a response to the therapy received maintenance treatment with the same antibody as they received for induction for up to 2 years. Results were published online ahead of print in the New England Journal of Medicine.

Patients were followed for a median of 34.5 months. At a planned interim analysis, obinutuzumab showed a significantly lower risk of progression, relapse, or death. The 3-year rate of progression-free survival was 80% with obinutuzumab, and 73.3% with rituximab, and the hazard ratio (HR) for progression, relapse, or death was 0.66 (95% CI, 0.51–0.85; P = .001).

There were 35 deaths in the obinutuzumab group, compared with 46 in the rituximab group, resulting in an HR for death of 0.75 (95% CI, 0.49–1.17; P = .21). Response rates were similar at the end of the induction phase, at 88.5% with obinutuzumab and 86.9% with rituximab (P = .33). Event-free survival was better with obinutuzumab, with an HR of 0.65 (95% CI, 0.51–0.83; P < .001).

Adverse events of grade 3 to 5 were more common with obinutuzumab therapy, at 74.6% compared with 67.8%. Serious adverse events (AEs) were also more common, occurring in 46.1% and 39.9% of patients, respectively; 4% of obinutuzumab patients and 3.4% of rituximab patients experienced an AE resulting in death. Infusion-related events were most common, occurring in 59.3% of obinutuzumab patients and in 48.9% of rituximab patients.

“The results of this large collaborative trial show that the replacement of rituximab with obinutuzumab in the context of immunochemotherapy and maintenance therapy in patients with previously untreated follicular lymphoma resulted in significantly longer progression-free survival,” the authors concluded.

Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Related Content